US equities
|
SPCX
$166.34
▲+4.65%
NVDA
$236.86
▲+1.24%
MU
$1,064.86
▼-0.93%
TSLA
$377.40
▲+1.84%
MSFT
$526.12
▲+1.66%
SNDK
$1,713.12
▼-0.40%
INTC
$117.28
▼-1.72%
META
$745.07
▲+2.33%
SPCX
$166.34
▲+4.65%
NVDA
$236.86
▲+1.24%
MU
$1,064.86
▼-0.93%
TSLA
$377.40
▲+1.84%
MSFT
$526.12
▲+1.66%
SNDK
$1,713.12
▼-0.40%
INTC
$117.28
▼-1.72%
META
$745.07
▲+2.33%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Gossamer Bio, Inc. - Common Stock
(NQ:
GOSS
)
10.37
-0.34 (-3.17%)
Delayed Quote
Updated: 11:46 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gossamer Bio, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
June 01, 2026
From
The Schall Law Firm
Via
Business Wire
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 31, 2026
From
Schall Law
Via
GlobeNewswire
GOSSAMER BIO DEADLINE MONDAY JUNE 1st: Bragar Eagel & Squire, P.C. Urges Gossamer Bio, Inc. (NASDAQ:GOSS) Investors with Large Losses to Contact the Firm Before Monday June 1st
May 29, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
Deadline Soon: Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
May 29, 2026
From
The Law Offices of Frank R. Cruz
Via
Business Wire
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 28, 2026
From
Schall Law
Via
GlobeNewswire
GOSSAMER DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – GOSS
May 27, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
Gossamer Bio (GOSS) Q1 2026 Earnings Transcript
↗
May 27, 2026
Gossamer Bio (GOSS) Q1 2026 Earnings Transcript
Via
The Motley Fool
Bragar Eagel & Squire, P.C. Urges Gossamer Bio, Inc. (NASDAQ:GOSS) Investors with Large Losses to Contact the Firm Before Monday June 1st
May 26, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines – GOSS
May 26, 2026
From
Pomerantz LLP
Via
GlobeNewswire
DEADLINE APPROACHING: Berger Montague Advises Gossamer Bio, Inc. (NASDAQ: GOSS) Investors to Inquire About a Securities Fraud Class Action by June 1, 2026
May 26, 2026
From
Berger Montague
Via
GlobeNewswire
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 25, 2026
From
Schall Law
Via
GlobeNewswire
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 21, 2026
From
Schall Law
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines – GOSS
May 19, 2026
From
Pomerantz LLP
Via
GlobeNewswire
These stocks are moving in today's session
↗
May 18, 2026
Via
Chartmill
GOSS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026
May 18, 2026
From
Faruqi & Faruqi, LLP
Via
Business Wire
Let's have a look at the top gainers and losers in the middle of the day of today's session.
↗
May 18, 2026
Via
Chartmill
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 18, 2026
From
Schall Law
Via
GlobeNewswire
Which stocks are gapping on Monday?
↗
May 18, 2026
Via
Chartmill
Gossamer Bio Q1 Earnings Call Highlights
↗
May 18, 2026
Gossamer Bio (NASDAQ:GOSS) said it is moving ahead with plans to seek U.S. approval for seralutinib in pulmonary arterial hypertension, outlining a September 2026 target for a New Drug Application...
Via
MarketBeat
Topics
Earnings
Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support
May 18, 2026
From
Gossamer Bio, Inc.
Via
Business Wire
Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update
May 18, 2026
From
Gossamer Bio, Inc.
Via
Business Wire
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 15, 2026
From
Schall Law
Via
GlobeNewswire
Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026
May 15, 2026
From
Gossamer Bio, Inc.
Via
Business Wire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GOSS
May 13, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines – GOSS
May 12, 2026
From
Pomerantz LLP
Via
GlobeNewswire
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 12, 2026
From
Schall Law
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Gossamer Investors that a Class Action Lawsuit Has Been Filed Against Gossamer Bio, Inc. (NASDAQ:GOSS) and Encourages Investors with Large Losses to Contact the Firm
May 11, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GOSS
May 10, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 08, 2026
From
Schall Law
Via
GlobeNewswire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GOSS
May 07, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
